35results about How to "Increased gene expression levels" patented technology

The present invention provides methods for increasing oil content in Jatropha Curcas L. plants. The invention further provides the cDNA and protein sequences of Jatropha acetyl CoA carboxylase (ACCase) and methods for cloning and expressing the Jatropha ACCase gene to produce transgenic plants with increased oil content.

The present invention relates to vectors, compositions and methods for delivering transgenes into mammalian cells. The invention also relates to genetic constructs and recombinant cells suitable to produce such transgenes. The invention more particularly relates to a vector suitable for transgene delivery into mammalian cells, wherein said vector comprises a chimeric genetic construct comprising a transgene operably linked to at least two distinct posttranscriptional regulatory elements functional in mammalian cells. This invention can be used in experimental, research, therapeutic, prophylactic or diagnostic areas.

The invention is concerned with the systematic elucidation and identification of regulatory sequences. The invention provides among others screenings and detection methods with which regulatory sequences can be identified. The invention further provides regulatory sequences and use thereof in various fields such as, but not limited to, protein production, diagnostics, transgenic plants and animals, and the therapeutic field.

The present invention provides methods for inhibiting the growth of breast cancer cells and methods for treating breast cancers expressing Wilms' Tumor 1 (WT1) gene product using a WT1 antisense oligonucleotide. It further provides methods of predicting breast cancer progression and methods for the screening of candidate substances for activity against breast cancer.

The present invention relates to a highly efficient eukaryotic expression vector containing an exogenous transcription regulatory element which comprises a promoter/enhancer and the nucleotide sequence upstream of the translation initiation codon derived from human cytomegalovirus (HCMV) immediately early (IE) gene or human elongation factor 1alpha (EF1alpha) gene.

Methods for the production of PHCA are disclosed. The methods rely on the tight gene expression of genetic constructs encoding polypeptides having tyrosine ammonia lyase activity. Promoters of choice are arabinose inducible.

The invention belongs to the field of biological genetic engineering, and provides a dual-promoter inducible secretable shuttle plasmid. The shuttle plasmid consists of an enzyme cutting Escherichia coli pET-28a plasmid and an enzyme cutting bacillus subtilis pE194 plasmid, wherein a lysozyme-antibacterial peptide functional fragment and an antibacterial peptide gene are inserted into the enzyme cutting Escherichia coli pET-28a plasmid. The invention also provides a method for constructing the dual-promoter inducible secretable shuttle plasmid. The shuttle plasmid is transferred to a prokaryote to express proteins such as toxalbumin, cecropin and the like in a fusion mode without toxicity to a host. The shuttle plasmid constructed by the method can be induced by IPTG or lactose to improve gene expression level; the shuttle plasmid is also suitable for exocrine expression, and a target protein for the exocrine expression is convenient to process and is not polluted by endotoxin; and because the shuttle plasmid has dual functional promoters, different genes can be inserted in appropriate correct directions for gene expression.

The invention discloses a polyurethane/decellularized fibrous ring matrix fibrous scaffold, which has a core-shell structure. The polyurethane is used as a core and the decellularized fibrous ring matrix is used as a shell. Besides, the invention also discloses a preparation method of the polyurethane/acellular fibrous ring matrix fibrous scaffold. Polyurethane is used as a solute of an internal solution and a decellularized fibrous ring matrix is used as a solute of an external solution; coaxial electrostatic spinning is performed to obtain a polyurethane/acellular fibrous ring matrix fibrousscaffold. During the coaxial electrostatic spinning process, the flow velocity of the internal solution is 0.4 to 0.6 mL/h, the flow velocity of the external solution is 0.15 to 0.25 mL/h, the voltage of the mandrel is 15 to 17 kV, and the rotating speed of the mandrel is 180 to 220 rpm. In addition, the invention also discloses application of the polyurethane/acellular fibrous ring matrix fibrous scaffold in preparation of drugs for treating intervertebral disc degenerative diseases.

The invention belongs to the field of medicine, and particularly relates to an application of oxidized high-density lipoprotein. The oxidized high-density lipoprotein is used as a target or a marker of calcified aortic valve diseases. The oxidized high-density lipoprotein and/or an oxidized high-density lipoprotein detection reagent can be used for preparing a diagnostic agent of the calcified aortic valve diseases, monitoring a concentration of the oxidized high-density lipoprotein and predicting occurrence and a progress of the calcified aortic valve diseases. An inhibitor or blocker of theoxidized high-density lipoprotein can also be used for preparing medicine for treating the calcified aortic valve diseases and treating the calcified aortic valve diseases. The oxidized high-density lipoprotein and/or the oxidized high-density lipoprotein detection reagent can also be used for preparing a screening agent of calcified aortic valve disease treatment medicine and screening the medicine for treating the calcified aortic valve diseases. The application of the oxidized high-density lipoprotein provides a new way and basis for clinical diagnosis and treatment of the calcified aorticvalve diseases.

The invention relates to the field of biotechnology. Hematopoietic stem cell transplantation is a unique way of curing malignant hematologic diseases, but the complications in the hematopoietic stem cell transplantation process are still key factors causing death of the patient, and the most prominent is graft-versus-host disease (FVHD). How to prevent and treat the GVHD is a severe challenge to hematopoietic stem cell transplantation. The invention provides an adenovirus vector carrying inducible co-stimulater (ICOS) gene, and a construction method for the adenovirus vector. After the adenovirus vector transfects mesenchymal stem cells (MSCs), an aim of preventing and treating the GVHD is fulfilled by a method of combining the effect of the ICOS in the T lymphocyte activating process and the effect of the MSCs in the immune adjusting process.

The present invention is directed to assay methods for inflammatory myopathies and microarray plates that can be used in carrying out these assays.

The present disclosure is directed to a novel, unexpected approach of expressing exogenous gene(s) at increased levels by predictably, optionally irreversibly, incorporating the gene(s) into a region of increased gene expression (RIDGE) on a chromosome of a host cell. This approach is accomplished by identification of RIDGE(s) and further by integration of integrase-specific sites (e.g., attP or attB) in the presence of or mediated by integrase. The approach renders a high level of gene expression; predictability of the location of the exogenous genes, elimination of genetic instability or unwanted phenotype; and reduction of time and cost in optimizing protein production in host cells, which will be every useful in the production of therapeutic, prophylactic, and diagnostic proteins.

The invention discloses an agrobacterium rhizogenes-mediated one-step transformation method for hairy roots of caragana intermediary. The method comprises the following steps: S1, electrically transforming plasmids containing e-GFP expression vectors into agrobacterium rhizogenes K599 competent cells; S2, preparing an agrobacterium rhizogenes bacterial suspension with the OD600nm of 0.8 to 0.95, and adding acetosyringone into the agrobacterium rhizogenes bacterial suspension; S3, culturing bacterial paste for infection; and S4, selecting a caragana intermedia seedling, obliquely cutting a part which is 1cm below a cotyledonary node of the seedling, discarding the lower part, infecting a cut, then transplanting the seedling back into soil, pouring a 1/4B5 culture medium to the seedling, and putting the seedling into an illumination incubator for culturing. According to the method, the caragana intermediary hairy roots are converted through a one-step method, so that the genes are over-expressed in the hairy roots, and compared with a tissue culture method for converting the caragana intermediary hairy roots, the method is simpler to operate, does not need to prepare sterile seedlings, and is shorter in detection time, high in gene expression level and convenient to detect.

The present invention provides a poxvirus-derived promoter, a vector comprising the same, a method for expressing a transgene using the promoter, and use of the vector in the prevention or treatment of a disease. A promoter according to the present invention can be used for induction of strong expression of a transgene.

The invention provides an intestinal mucosa protective agent applied to penaeus vannamei. The intestinal mucosa protective agent is prepared from the following components in parts by weight: 15-20 parts of glutamine dipeptide, 10-15 parts of arginine, 5-10 parts of inositol, 10-15 parts of radix puerariae, 10-15 parts of radix astragali seu hedysari, 15-20 parts of chitosan oligosaccharide, 5-10 parts of radix salviae miltiorrhizae and 10-15 parts of vitamin C phosphate. All the components of the health-care agent are crushed to 200 meshes and are uniformly mixed. In a feed processing process,the intestinal mucosa protective agent is used as an additive and is added according to the ratio of 0.1 percent to 0.2 percent to prepare functional feed. In a culture production process, the intestinal mucosa protective agent is fed for one period every 10 days from the last ten-day period of June to the last ten-day period of August every year. The intestinal mucosa protective agent is obtained from scientific experiment results and has scientific compatibility; an operation method is simple and convenient. The protective agent has a remarkable protection effect on intestinal mucosa of thepenaeus vannamei and can be used for remarkably reducing the occurrence rate of jejunum and empty stomach and white stool diseases of the penaeus vannamei and remarkably improving the culture economic benefits of the penaeus vannamei.

The invention relates to a constitutive promoter and application thereof. The nucleotide sequence of the constitutive promoter comprises the following sequence (a) or (b): (a) nucleotide sequence disclosed as SEQ ID NO:1; or (b) nucleotide sequence crossbred with the nucleotide sequence defined in (a) under strict conditions. The constitutive promoter generally has activity in most tissues and many types of cells of plants, and obviously enhances the expression level of the target heterologous nucleotide sequence in plant tissues especially in leaves and stems.